概括
使用左内乳腺动脉 (LIMA) 和软静脉移植 (SVG) 进行冠状动脉旁路手术,在无症状心肌梗塞后的患者中显示出优异的长期存活率和移植通透性. 这些发现支持对精选个体进行手术重血管化.
科学领域:
- 心脏病学 心脏病学
- 心脏外科手术 心脏外科手术
- 血管外科 血管外科
背景情况:
- 无症状冠状动脉病 (CAD) 发生心肌梗塞 (MI) 后,在最佳管理方面提出了临床挑战.
- 在这个特定的患者队列中,移植透视性和手术重血管化的长期结果需要进一步研究.
研究的目的:
- 为了评估冠状动脉疾病进行手术治疗的无症状患者的长期存活,临床状态和移植通透性.
- 评估心肌梗塞再血管化的安全性和有效性,在选择的后心肌梗塞患者.
主要方法:
- 一系列连续的17名无症状,患有显著冠状动脉疾病的患者接受了手术重血管化.
- 患者接受左内乳腺动脉 (LIMA) 移植到左前下垂冠状动脉,有些人也接受了沙静脉移植 (SVG).
- 随访包括临床评估和手术后血管造影,平均75个月.
主要成果:
- 在研究队列中没有观察到手术后或晚期死亡率.
- 手术后血管造影显示了高穿透率:12个LIMA移植中的11个和所有SVG移植都是穿透的.
- 大多数患者在至少5.5年的随访后仍然无症状和完全活跃,没有间歇性心肌梗塞.
结论:
- 手术心肌复血管化是选择性无症状心肌梗塞后患有关键冠状动脉狭窄症的患者的安全有效的治疗选择.
- 长期高的移植通透率,特别是LIMA移植,有助于有利的临床结果和持续的症状缓解.
更多相关视频
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
05:25Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft
Published on: September 15, 2023
相关概念视频
01:30Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...